

associated with this strategy. Given that Pgp (and other transport system) is ubiquitously expressed throughout the body and serves primarily as a detoxification mechanism, is it prudent to inhibit this system? By enhancing CNS delivery through reduction Pgp-mediated efflux across the BBB, will potentially toxic compounds also accumulate? More, importantly, will this open the door for toxins ingested in the diet to gain access to the systemic circulation due to nonselective inhibition of intestinal Pgp? Alternatively, Pgp may be just one of many systems in place and can therefore be modified without risk. These issues remain to be resolved. In the meantime, the quest for the magic bullet continues.

## REFERENCES

1. Giacomini KM. Membrane transporters in drug disposition. *J Pharmacol Biopharm* 1997; 25(6):731–741.
2. Meijer DKF, Mol WEM, Muller M, Kurz G. Carrier-mediated transport in the hepatic distribution and elimination of drugs, with special reference to the category of organic cations. *J Pharmacol Biopharm* 1990; 18(1):35–70.
3. Oude Elferink RPJ, Meijer DKF, Kuipers F, Jansen PLM, Groen AK, Groothuis GMM. Hepatobiliary secretion of organic compounds; molecular mechanisms of membrane transport. *Biochim Biophys Acta* 1995; 1241: 215–268.
4. Meijer DKF, Smit JW, Muller M. Hepatobiliary elimination of cationic drugs: the role of P-glycoproteins and other ATP-dependent transporters. *Adv Drug Del Rev* 1997; 25:159–200.
5. Faber KN, Muller M, Jansen PLM. Drug transport proteins in the liver. *Adv Drug Del Rev* 2003; 55:107–124.
6. Suzuki H, Sugiyama Y. Transport of drugs across the hepatic sinusoidal membrane: sinusoidal drug influx and efflux in the liver. *Sem Liver Dis* 2000; 20:251–263.
7. Hooiveld GJEJ, von Montfoort JE, Meijer DKF, Muller M. Function and regulation of ATP-binding cassette transport proteins involved in hepatobiliary transport. *Eur J Pharm Sci* 2001; 12:525–543.
8. Hagenbuch B, Meier PJ. Sinusoidal (basolateral) bile salt uptake systems of hepatocytes. *Sem Liver Dis* 1996; 16:129–136.
9. Kim RB. Transporters and xenobiotic disposition. *Toxicology* 2002; 27: 181–182.
10. Tirona RG, Kim RB. Pharmacogenomics of organic anion-transporting polypeptides (OATP). *Adv Drug Del Rev* 2002; 54:1343–1352.
11. Ayrton A, Morgan P. Role of transport proteins in drug absorption, distribution and excretion. *Xenobiotica* 2001; 31:469–497.
12. Borst P, Oude Elferink R. Mammalian ABC transporters in health and disease. *Annu Rev Biochem* 2002; 71:537–592.
13. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. *Adv Drug Del Rev* 2003; 55:3–29.